Pure Global
NCT05684705

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

A Single Center, Open-label Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 (Rifabutin for Infusion) in Healthy Participants
BioVersys AG·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bacterial Infections
Drug/Device/Intervention
BV100
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
BioVersys AG
Location
Vienna, Austria
Timeline & enrollment
Phase
Phase 1
Start date
Mar 01, 2023
End date
Dec 01, 2023
Enrollment
40 participants
Primary outcome

To assess plasma concentration of rifabutin in healthy participants,To assess epithelial lining fluid concentration of rifabutin in healthy participants,To assess concentration of rifabutin in alveolar macrophages of healthy participants

Summary

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous
 Administrations of BV100

ICD-10 classifications
Bacterial infection, unspecifiedBacterial, viral and other infectious agentsOther bacterial intestinal infectionsOther bacterial diseasesOther specified bacterial intestinal infections
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05684705
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05684705 through Pure Global AI's free database. This Phase 1 trial is sponsored by BioVersys AG and is currently Not yet recruiting. The study focuses on Bacterial Infections. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.